European Access for Chinese Biotech
What is Europe worth to your asset?
For Chinese biotechs, Europe is more than another market. Done right, it adds value to your asset worldwide — whether you launch, partner, or out-license.
Approval opens the door. Value is won after it: EMA approval → reimbursement → the right price, protected globally → higher global asset value.
Why Europe?
Revenue. Access major pharmaceutical markets, reach new patients and diversify revenues.
Partnering. Strengthen your asset’s attractiveness to international licensing and development partners — European readiness is what a Western partner scrutinises in due diligence.
Global development. Leverage your Chinese clinical evidence for European approval and access, supporting broader international expansion.
Global pricing. Optimise launch sequencing and manage international pricing exposure, including US MFN.
Three questions to answer before Europe
Is our evidence enough? We assess whether your Chinese clinical evidence meets European regulatory and payer requirements — and identify the critical gaps before a partner finds them.
What is Europe worth? We estimate eligible patients, achievable prices and reimbursement prospects to quantify your asset’s European commercial potential.
How should we enter? Out-license, partner or launch independently? We evaluate the options against your commercial objectives and investment capacity.
A typical case
A Chinese oncology asset shows strong clinical results — but its pivotal trial used a comparator that is no longer standard of care in Europe. EMA approval alone is not enough; the challenge is demonstrating comparative value to European payers. Knowing this early changes the plan — and the partner conversation.
How we get there
- Size the opportunity — eligible patients and European commercial potential.
- Leverage Chinese evidence — what transfers to European requirements, and what doesn’t.
- Optimise pricing strategy — achievable price and international (MFN/IRP) exposure.
- Build the case for reimbursement — the comparative-value story European payers need.
- Choose your market-entry model — launch, partner or out-license.
European launch decisions have global pricing implications. We quantify the trade-offs to help you decide where and when to launch.
Start here — European Opportunity Assessment
A focused, fixed-scope assessment of your asset’s European evidence readiness, commercial potential and market-entry options — ending in one actionable recommendation: Proceed, Partner, or Defer.